Single Test Detects All Existing Strains of H5N1
|
By LabMedica International staff writers Posted on 06 Jun 2012 |
|
A bird flu diagnostic kit was successfully developed by scientists at a research institute and a hospital in Singapore.
The advanced kit enables doctors to rapidly detect all existing strains of H5N1 viruses in a single test with almost 100% accuracy. This will boost the public healthcare system and will aid pandemic preparedness worldwide against this highly infectious and often lethal disease.
The new H5N1 test kit is more accurately known as the H5N1 real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay. It is the only detection kit currently available on the market that can accurately and rapidly detect all known strains of the H5N1 avian Influenza A virus.
The current gold standard for H5N1 detection recommended by the World Health Organization (WHO; Geneva, Switzerland) is only able to detect three out of the 10 distinct genetic groups (clades 1, 2, and 3). To detect all existing strains of H5N1 with the WHO detection method is not possible.
Codeveloped by Dr. Masafumi Inoue, a senior research scientist and project director of technology development from the Experimental Therapeutics Center (ETC) under the Agency for Science and Technology Research (A*STAR; Singapore) and Dr Timothy Barkham, a senior consultant of Laboratory Medicine from Tan Tock Seng Hospital (TTSH; Singapore), the newly launched H5N1 test kit has been clinically validated by several hospitals in Southeast Asia.
The new test kit is compatible with the previously launched "4-plex" Influenza diagnostic kit. The latter is being used by several regional hospitals in Thailand. Using such multiplex assays enables simultaneous detection and differentiation of the different types of influenza infection in a single test, which will save laboratories time and expense.
"We are excited to be able to contribute to the fight against H5N1 virus with our expertise and know-how. Our technology has greatly simplified and accelerated the process of detection and identification of new H5N1 variants. Such information is especially critical when the virus mutates to become more dangerous, such as in drug resistance." said Dr Inoue.
Related Links:
Agency for Science and Technology Research
Tan Tock Seng Hospital
World Health Organization
The advanced kit enables doctors to rapidly detect all existing strains of H5N1 viruses in a single test with almost 100% accuracy. This will boost the public healthcare system and will aid pandemic preparedness worldwide against this highly infectious and often lethal disease.
The new H5N1 test kit is more accurately known as the H5N1 real-time Reverse Transcription Polymerase Chain Reaction (RT-PCR) assay. It is the only detection kit currently available on the market that can accurately and rapidly detect all known strains of the H5N1 avian Influenza A virus.
The current gold standard for H5N1 detection recommended by the World Health Organization (WHO; Geneva, Switzerland) is only able to detect three out of the 10 distinct genetic groups (clades 1, 2, and 3). To detect all existing strains of H5N1 with the WHO detection method is not possible.
Codeveloped by Dr. Masafumi Inoue, a senior research scientist and project director of technology development from the Experimental Therapeutics Center (ETC) under the Agency for Science and Technology Research (A*STAR; Singapore) and Dr Timothy Barkham, a senior consultant of Laboratory Medicine from Tan Tock Seng Hospital (TTSH; Singapore), the newly launched H5N1 test kit has been clinically validated by several hospitals in Southeast Asia.
The new test kit is compatible with the previously launched "4-plex" Influenza diagnostic kit. The latter is being used by several regional hospitals in Thailand. Using such multiplex assays enables simultaneous detection and differentiation of the different types of influenza infection in a single test, which will save laboratories time and expense.
"We are excited to be able to contribute to the fight against H5N1 virus with our expertise and know-how. Our technology has greatly simplified and accelerated the process of detection and identification of new H5N1 variants. Such information is especially critical when the virus mutates to become more dangerous, such as in drug resistance." said Dr Inoue.
Related Links:
Agency for Science and Technology Research
Tan Tock Seng Hospital
World Health Organization
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
Repetitive Pipette
VWR® Stepper Pro
New
Prefilled Tubes
Prefilled 5.0ml Tubes
Latest Microbiology News
- New Bacterial Target Identified for Early Detection of Noma
- Genomic Analysis Links Emerging Streptococcal Strains to Specific Infections
- Rapid Urine Test Speeds Antibiotic Selection for UTIs
- WHO Endorses Rapid Point-of-Care Testing to Improve TB Detection
- Breath Analysis Approach Offers Rapid Detection of Bacterial Infection
- Study Highlights Accuracy Gaps in Consumer Gut Microbiome Kits
- WHO Recommends Near POC Tests, Tongue Swabs and Sputum Pooling for TB Diagnosis
- New Imaging Approach Could Help Predict Dangerous Gut Infection
- Rapid Sequencing Could Transform Tuberculosis Care
- Blood-Based Viral Signature Identified in Crohn’s Disease
- Hidden Gut Viruses Linked to Colorectal Cancer Risk
- Three-Test Panel Launched for Detection of Liver Fluke Infections
- Rapid Test Promises Faster Answers for Drug-Resistant Infections
- CRISPR-Based Technology Neutralizes Antibiotic-Resistant Bacteria
- Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease
- AI-Powered Platform Enables Rapid Detection of Drug-Resistant C. Auris Pathogens
Channels
Clinical Chemistry
view channel
New CLIA Status Brings Mass Spectrometry Steroid Testing to Routine Labs
Steroid hormone measurement is a core application of clinical mass spectrometry, which is widely regarded as a diagnostic gold standard. Access to these high-specificity methods has often been constrained... Read more
Study Shows Dual Biomarkers Improve Accuracy of Alzheimer’s Detection
Alzheimer’s disease develops slowly, and biological changes can appear in blood many years before symptoms. While plasma assays for phosphorylated tau offer earlier detection, discerning whether these... Read more
Molecular Diagnostics
view channel
Whole Genome Sequencing in Routine Care Expands Rare Disease Detection
Rare diseases often involve prolonged diagnostic journeys that delay clinical decision-making and complicate family planning. As phenotypes become more heterogeneous, sequencing-based methods are increasingly... Read more
New AI Tool Improves Detection of Genetic Causes in Rare Disorders
Families affected by rare diseases often endure years of inconclusive testing and fragmented referrals before a definitive diagnosis. Despite broad access to genomic sequencing, many patients remain undiagnosed,... Read more
Hematology
view channel
Rapid Cartridge-Based Test Aims to Expand Access to Hemoglobin Disorder Diagnosis
Sickle cell disease and beta thalassemia are hemoglobin disorders that often require referral to specialized laboratories for definitive diagnosis, delaying results for patients and clinicians.... Read more
New Guidelines Aim to Improve AL Amyloidosis Diagnosis
Light chain (AL) amyloidosis is a rare, life-threatening bone marrow disorder in which abnormal amyloid proteins accumulate in organs. Approximately 3,260 people in the United States are diagnosed... Read more
Immunology
view channel
FDA Approval Expands Use of PD-L1 Companion Diagnostic in Esophageal and GEJ Carcinomas
Esophageal and gastroesophageal junction carcinomas (GEJ) have a poor prognosis, with approximately 16,250 deaths in the United States in 2025 and a five-year relative survival of 21.9%.... Read more
Study Identifies Inflammatory Pathway Driving Immunotherapy Resistance in Bladder Cancer
Bladder cancer remains a prevalent malignancy with variable responses to immune checkpoint inhibitors. Clinicians often observe elevated C-reactive protein and interleukin-6 in affected patients, yet the... Read more
Pathology
view channel
AI Tool Predicts Patient-Specific Chemotherapy Benefit in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer is typically guided by recurrence risk and population-level averages rather than patient-specific benefit. However, existing clinicopathologic... Read more
AI-Based Pathology Model Guides Chemotherapy Decisions in Breast Cancer
Selecting adjuvant chemotherapy for early-stage breast cancer remains a difficult decision because only a subset benefits and many undergo toxicity without gain. Genomic assays can help but are costly,... Read more
Technology
view channel
New AI Tool Enables Rapid Treatment Selection in Pediatric Leukemia
Children with T-cell acute lymphoblastic leukemia face an aggressive disease that remains difficult to treat. Although remission rates have improved, many survivors experience long-term effects from intensive... Read more
Breakthrough Mass Spectrometry Design Could Enable Ultra-Low Abundance Detection
Mass spectrometry is central to identifying and quantifying molecules in complex biological samples, but conventional instruments typically analyze ions sequentially, which can limit detection of rare species.... Read more
Industry
view channel
Takara Bio USA and Hamilton Partner Partner to Automate NGS Library Preparation
Takara Bio USA, Inc. (San Jose, CA, USA), a wholly owned subsidiary of Takara Bio Inc., and Hamilton Company (Reno, NV, USA) announced a development and co-marketing agreement to deliver integrated, automated... Read more
